Innate Pharma Reports Results from the P-II Study (TELLOMAK) of Lacutamab for Sézary Syndrome
Shots:
- The P-II (TELLOMAK) study investigated the safety and efficacy of lacutamab monotx. in patients (n=56) with r/r Sézary syndrome who had undergone at least two previous systemic therapies incl. mogamulizumab
- The study results, at the data cut-off of May 1, 2023, depicted that the global confirmed ORR was 37.5% incl. 2 CRs, confirmed ORR in skin was 46.4% incl. 5 CRs, confirmed ORR in blood was 48.2% incl. 15 CRs, CBR (CR+PR+SD) was 87.5% and m-PFS was 8.0mos. with a favorable safety profile
- The company will highlight these results along with the data from study of SAR443579/IPH6101 for r/r acute myeloid leukemia (AML), B-cell acute lymphoblastic leukemia (B-ALL) or high-risk myelodysplasia at ASH’23
Ref: Innate Pharma | Image: Innate Pharma
Related News:- Innate Pharma Reports the US FDA’s Partial Clinical Hold on New Patient Enrolment of Lacutamab
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Shivani was a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She was covering news related to Product approvals, clinical trial results, and updates. We can be contacted at connect@pharmashots.com.
